The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for
DUBAI, UAE, Oct. 21, 2024 (GLOBE NEWSWIRE) — Human trafficking continues to be an issue in the UAE, particularly affecting foreign workers from Africa and South and Southeast Asia. Lured with false promises of high-paying jobs, victims arrive in the
NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class
Tripoli: National Oil Corporation (NOC) followed up yesterday on its plan to increase the production in 2024 and difficulties that affected implementing these targets.
The corporation held a series of meetings, including the production increase follo…